{"id":70593,"date":"2026-07-24T20:59:05","date_gmt":"2026-07-24T12:59:05","guid":{"rendered":"https:\/\/flcube.com\/?p=70593"},"modified":"2026-07-24T20:59:06","modified_gmt":"2026-07-24T12:59:06","slug":"harbour-biomed-issues-profit-alert-h1-revenue-expected-at-120-125m-on-strong-platform-licensing-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70593","title":{"rendered":"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Harbour BioMed<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2142:HKG\">HKG: 2142<\/a>) issued a positive profit alert today for its interim results ending June 30, 2026, forecasting <strong>first-half revenue of USD 120-125 million<\/strong>, representing <strong>19-24% year-over-year growth<\/strong>. The company projects <strong>adjusted net profit of USD 70-75 million<\/strong>, driven by successful execution of high-value strategic collaborations and strong recurring revenue from its proprietary technology platforms.<\/p>\n\n\n\n<h2 id=\"h-financial-guidance-h1-2026\" class=\"wp-block-heading\">Financial Guidance \u2013 H1 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Expected Range<\/th><th>YoY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>USD 120-125 million<\/td><td>+19% to +24%<\/td><\/tr><tr><td><strong>Adjusted Net Profit<\/strong><\/td><td>USD 70-75 million<\/td><td>Not disclosed<\/td><\/tr><tr><td><strong>Reporting Period<\/strong><\/td><td>Six months ended June 30, 2026<\/td><td>vs. H1 2025<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>24 Jul 2026<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-revenue-drivers-amp-business-model\" class=\"wp-block-heading\">Revenue Drivers &amp; Business Model<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Collaborations:<\/strong> Continued execution and deepening of <strong>high-value global partnerships<\/strong> with multinational pharmaceutical companies, innovative biotechs, and academic institutions<\/li>\n\n\n\n<li><strong>Platform Monetization:<\/strong> Successful conversion of <strong>Harbour Mice technology platforms<\/strong> into strong, recurring revenue streams through out-licensing agreements<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Income derived from multiple sources including:<\/li>\n\n\n\n<li><strong>Platform-based technology licensing<\/strong><\/li>\n\n\n\n<li><strong>Research and development services<\/strong><\/li>\n\n\n\n<li><strong>Milestone payments<\/strong> from existing collaborations<\/li>\n\n\n\n<li><strong>Market Recognition:<\/strong> High validation of the <strong>Harbour Mice platform<\/strong> by global industry leaders demonstrates the platform&#8217;s competitive differentiation and scientific robustness<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-nona-biosciences-growth-contribution\" class=\"wp-block-heading\">Nona Biosciences Growth Contribution<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Subsidiary Performance:<\/strong> <strong>Nona Biosciences<\/strong> has entered a phase of rapid growth, contributing significantly to Harbour BioMed&#8217;s overall financial performance<\/li>\n\n\n\n<li><strong>Platform Leadership:<\/strong> Nona&#8217;s <strong>H2L2 Harbour Mice platform<\/strong> has gained widespread adoption among multinational pharmaceutical companies seeking fully human antibody discovery capabilities<\/li>\n\n\n\n<li><strong>Revenue Pillar:<\/strong> Platform-based licensing and services from Nona represent a <strong>major revenue pillar<\/strong>, complementing Harbour BioMed&#8217;s internal drug development programs<\/li>\n\n\n\n<li><strong>Global Reach:<\/strong> Collaborations span across North America, Europe, and Asia-Pacific regions, providing geographic diversification and reducing dependency on single markets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-positioning-amp-competitive-advantages\" class=\"wp-block-heading\">Strategic Positioning &amp; Competitive Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform Focus:<\/strong> Unlike traditional biopharma companies dependent on drug candidates, Harbour BioMed has built a <strong>dual-engine business model<\/strong> combining platform licensing with internal pipeline development<\/li>\n\n\n\n<li><strong>Recurring Revenue Model:<\/strong> Licensing agreements provide predictable, long-term revenue streams that support continued R&amp;D investment and operational stability<\/li>\n\n\n\n<li><strong>Industry Validation:<\/strong> Partnerships with top-tier pharmaceutical companies serve as third-party validation of platform quality and scientific capabilities<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> Platform monetization generates non-dilutive funding that supports internal drug development without heavy reliance on equity financing<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-forward-outlook\" class=\"wp-block-heading\">Market Context &amp; Forward Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antibody Discovery Market:<\/strong> The global therapeutic antibody market continues to expand, with increasing demand for advanced discovery platforms that can generate developable, fully human antibodies<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Harbour BioMed competes with established platform companies like Regeneron, Kymab (Sanofi), and Ligand Pharmaceuticals, but differentiates through its unique Harbour Mice technology<\/li>\n\n\n\n<li><strong>Growth Sustainability:<\/strong> Strong H1 performance suggests the company&#8217;s platform strategy is gaining traction, with potential for continued growth through new partnership announcements and milestone achievements<\/li>\n\n\n\n<li><strong>Investment Implications:<\/strong> Profit alert may positively impact investor sentiment, particularly given the rarity of profitable biotechnology companies in the current market environment<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, revenue expectations, and business strategy. Actual results may differ due to partnership execution risks, milestone achievement timing, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,190,916],"class_list":["post-70593","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-harbour-biomed","tag-hkg-2142"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending June 30, 2026, forecasting first-half revenue of USD 120-125 million, representing 19-24% year-over-year growth. The company projects adjusted net profit of USD 70-75 million, driven by successful execution of high-value strategic collaborations and strong recurring revenue from its proprietary technology platforms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70593\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth\" \/>\n<meta property=\"og:description\" content=\"Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending June 30, 2026, forecasting first-half revenue of USD 120-125 million, representing 19-24% year-over-year growth. The company projects adjusted net profit of USD 70-75 million, driven by successful execution of high-value strategic collaborations and strong recurring revenue from its proprietary technology platforms.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70593\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T12:59:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-24T12:59:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70593#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70593\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth\",\"datePublished\":\"2026-07-24T12:59:05+00:00\",\"dateModified\":\"2026-07-24T12:59:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70593\"},\"wordCount\":496,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"Harbour BioMed\",\"HKG: 2142\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70593#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70593\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70593\",\"name\":\"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-24T12:59:05+00:00\",\"dateModified\":\"2026-07-24T12:59:06+00:00\",\"description\":\"Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending June 30, 2026, forecasting first-half revenue of USD 120-125 million, representing 19-24% year-over-year growth. The company projects adjusted net profit of USD 70-75 million, driven by successful execution of high-value strategic collaborations and strong recurring revenue from its proprietary technology platforms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70593#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70593\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70593#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth - Insight, China&#039;s Pharmaceutical Industry","description":"Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending June 30, 2026, forecasting first-half revenue of USD 120-125 million, representing 19-24% year-over-year growth. The company projects adjusted net profit of USD 70-75 million, driven by successful execution of high-value strategic collaborations and strong recurring revenue from its proprietary technology platforms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70593","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth","og_description":"Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending June 30, 2026, forecasting first-half revenue of USD 120-125 million, representing 19-24% year-over-year growth. The company projects adjusted net profit of USD 70-75 million, driven by successful execution of high-value strategic collaborations and strong recurring revenue from its proprietary technology platforms.","og_url":"https:\/\/flcube.com\/?p=70593","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-24T12:59:05+00:00","article_modified_time":"2026-07-24T12:59:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70593#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70593"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth","datePublished":"2026-07-24T12:59:05+00:00","dateModified":"2026-07-24T12:59:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70593"},"wordCount":496,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","Harbour BioMed","HKG: 2142"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70593#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70593","url":"https:\/\/flcube.com\/?p=70593","name":"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-24T12:59:05+00:00","dateModified":"2026-07-24T12:59:06+00:00","description":"Harbour BioMed (HKG: 2142) issued a positive profit alert today for its interim results ending June 30, 2026, forecasting first-half revenue of USD 120-125 million, representing 19-24% year-over-year growth. The company projects adjusted net profit of USD 70-75 million, driven by successful execution of high-value strategic collaborations and strong recurring revenue from its proprietary technology platforms.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70593#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70593"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70593#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Issues Profit Alert: H1 Revenue Expected at $120-125M on Strong Platform Licensing Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70593"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70593\/revisions"}],"predecessor-version":[{"id":70594,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70593\/revisions\/70594"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}